Medicina
Departamento
Semmelweis University
Budapest, HungríaPublicaciones en colaboración con investigadores/as de Semmelweis University (10)
2024
-
Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Clinical Cancer Research, Vol. 30, Núm. 4, pp. 824-835
2023
-
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
International Journal of Molecular Sciences, Vol. 24, Núm. 10
2022
2021
-
Genetically determined telomere length and multiple myeloma risk and outcome
Blood Cancer Journal, Vol. 11, Núm. 4
-
Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*
British Journal of Dermatology, Vol. 184, Núm. 3, pp. 524-531
-
Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*
British Journal of Dermatology, Vol. 184, Núm. 4, pp. 722-730
2015
-
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
Annals of Neurology, Vol. 77, Núm. 3, pp. 425-435
-
Type 2 diabetes-related variantsinfluence the risk of developing multiple myeloma: Results from the IMMEnSE consortium
Endocrine-Related Cancer, Vol. 22, Núm. 4, pp. 545-559
2014
-
Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations - An extensive replication of the associations from the candidate gene era
Cancer Epidemiology Biomarkers and Prevention, Vol. 23, Núm. 4, pp. 670-674
2012
-
Mortality after surgery in Europe: A 7 day cohort study
The Lancet, Vol. 380, Núm. 9847, pp. 1059-1065